Lyra Therapeutics Inc
$ 4.50
7.40%
04 Dec - close price
- Market Cap 7,987,000 USD
- Current Price $ 4.50
- High / Low $ 4.56 / 3.93
- Stock P/E N/A
- Book Value -2.63
- EPS -22.90
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -4.04 %
- 52 Week High 34.00
- 52 Week Low 2.84
About
Lyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to transforming the treatment of ear, nose, and throat (ENT) disorders through its innovative drug delivery technologies. The company leverages its proprietary platforms to develop therapies that provide sustained medication release, thereby enhancing patient adherence and improving clinical outcomes for chronic conditions. With a diverse pipeline of product candidates at various stages of development, Lyra is strategically positioned to address significant unmet medical needs in the ENT space, showcasing potential for substantial growth within the specialty pharmaceutical sector.
Analyst Target Price
$11.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-04-28 | 2025-03-19 | 2024-11-05 | 2024-08-14 | 2024-04-30 | 2024-03-21 | 2023-11-07 | 2023-08-08 | 2023-05-12 | 2023-03-29 |
| Reported EPS | -3.38 | -5.2194 | -0.13 | -0.1419 | -0.1385 | -0.74 | -0.35 | -0.22 | -0.27 | -0.32 | -0.44 | -0.38 |
| Estimated EPS | -0.185 | -0.165 | -0.1367 | -0.13 | -0.205 | -0.33 | -0.26 | -0.31 | -0.32 | -0.42 | -0.36 | -0.41 |
| Surprise | -3.195 | -5.0544 | 0.0067 | -0.0119 | 0.0665 | -0.41 | -0.09 | 0.09 | 0.05 | 0.1 | -0.08 | 0.03 |
| Surprise Percentage | -1727.027% | -3063.2727% | 4.9012% | -9.1538% | 32.439% | -124.2424% | -34.6154% | 29.0323% | 15.625% | 23.8095% | -22.2222% | 7.3171% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LYRA
2025-10-17 14:53:06
Lyra Therapeutics (LYRA) announced that results from its Phase 3 ENLIGHTEN 2 study of LYR-210 for Chronic Rhinosinusitis (CRS) will be presented at AAO-HNSF 2025. The study found LYR-210 significantly improved symptoms and quality of life in CRS patients, demonstrating a favorable safety profile. LYR-210 is a drug-eluting sinonasal implant designed for sustained drug delivery over 24 weeks in an in-office procedure.
2025-03-13 16:01:00
Lyra Therapeutics reported its fourth quarter and full year 2024 financial results, alongside a corporate update focusing on the upcoming ENLIGHTEN 2 pivotal Phase 3 trial results for its LYR-210 treatment in CRS patients, expected in Q2 2025. The company also detailed positive post-hoc data analyses for LYR-210 in CRS patients with nasal polyps and announced plans for a reverse stock split to maintain Nasdaq listing compliance. Financially, Lyra ended 2024 with $40.6 million in cash, projecting liquidity into Q1 2026, and reported a net loss of $93.4 million for the full year.
2025-02-06 07:05:00
Lyra Therapeutics announced positive results from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a treatment for chronic rhinosinusitis (CRS) without nasal polyps, meeting its primary and key secondary endpoints. While ENLIGHTEN 1 did not meet its primary endpoint, a pooled analysis showed a consistent positive trend for patients with small nasal polyps, informing future regulatory strategy. Despite strong short-term liquidity, the company faces financial challenges with negative EBITDA as it pursues FDA approval for LYR-210.
2024-05-21 00:00:00
Lyra Therapeutics has announced a significant reduction in its workforce, cutting 75% of its staff. The company is also seeking to sublease its facilities in Waltham and Watertown. This comes despite previous efforts to expand its real estate footprint and commercialization initiatives for a drug treating sinus inflammation.
2023-05-09 17:00:00
The sinusitis market is projected for significant growth between 2023 and 2032, driven by new drug launches, increased healthcare spending, and improved diagnosis across the 7MM. Leading pharmaceutical companies are actively developing novel therapies, which are expected to advance the market. Despite a robust pipeline, challenges such as the lack of a gold standard for management and the availability of off-label treatments may impact growth.
2023-02-06 15:06:12
J. Calnan & Associates, Inc. (JC&A) has announced the promotion of Chet Braun to Partner. Braun has been instrumental in expanding JC&A's presence in the life sciences and advanced technology markets, leading significant projects and solidifying the firm's reputation with key clients like Deciphera Pharmaceuticals and Biogen. His leadership, work ethic, and ability to mentor younger staff have been critical to his success and contributions to JC&A.
